Class summary at a glance.

Every drug in the alpha-Adrenergic Agonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 16tracked in Part D
CY24 Part D spend: $603.4Mcombined across class
Total Rx claims: 7.5M2.8M unique beneficiaries
Generic mfrs (active): 45across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Brimonidine

Brand: ALPHAGAN P · 4.1M Part D claims (CY24) · 1.3M beneficiaries · First FDA approval: 2001-07-10

11 generic mfrs 3 plans require PA

Low NADAC$0.525

→

Avg plan cost$12.42

Part D spend $267.0M 24× spread, current vs floor

Class share

44%

of class CY24 spend

View profile →

Epinephrine

Brand: Adrenalin · 875K Part D claims (CY24) · 718K beneficiaries · First FDA approval: 1987-12-22

6 generic mfrs 0 plans require PA Discontinued

Low NADAC$1.20

→

Avg plan cost$152.11

Part D spend $182.9M 127× spread, current vs floor

Class share

30%

of class CY24 spend

View profile →

Midodrine

2.5M Part D claims (CY24) · 761K beneficiaries · First FDA approval: 2003-09-11

13 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.073

→

Avg plan cost$0.108

Part D spend $153.5M 1× spread, current vs floor

Class share

25%

of class CY24 spend

View profile →

Ephedrine

Brand: Akovaz · 12 Part D claims (CY24) · 12 beneficiaries · First FDA approval: 2017-02-16

12 generic mfrs

Low NADAC—

→

Avg plan cost—

Part D spend $251

Class share

of class CY24 spend

View profile →

Adrenalin (Epinephrine)

— Part D claims (CY24) · First FDA approval: 2018-09-21

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Adrenalin(R)

— Part D claims (CY24) · First FDA approval: 2018-09-19

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Auvi-Q

— Part D claims (CY24) · First FDA approval: 2012-11-15

Brand-only (no generics)

Low NADAC$297.57

→

Avg plan cost$297.60

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Brimonidine and Timolol

Brand: Brimonidine Tartrate/Timolol Maleate · — Part D claims (CY24) · First FDA approval: 2022-04-13

Brand-only (no generics) 0 plans require PA

Low NADAC$2.30

→

Avg plan cost$2.73

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Brompheniramine Maleate, Pseudoephedrine Hydrochloride, and Dextromethorphan Hydrobromide

Brand: Brompheniramine Maleate, Pseudoephedrine Hydrochloride and Dextromethorphan Hydrobromide · — Part D claims (CY24) · First FDA approval: 2010-06-15

Brand-only (no generics)

Low NADAC$0.074

→

Avg plan cost$0.077

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Epinephrine 0.15 Pediatrics

Brand: Epinephrine Pediatrics · — Part D claims (CY24) · First FDA approval: 2010-04-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Epinephrine 0.3 Adults

— Part D claims (CY24) · First FDA approval: 2010-04-01

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Epinephrine In Sodium

Brand: Adrenalin (epinephrine in sodium chloride) · — Part D claims (CY24) · First FDA approval: 2024-10-04

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Epineprine

Brand: Adrenalin · — Part D claims (CY24) · First FDA approval: 2022-01-07

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidocaine Hci

Brand: Bruselix Cream · — Part D claims (CY24) · First FDA approval: 2018-08-25

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidocaine Hci and Epinephrine

— Part D claims (CY24) · First FDA approval: 2019-10-21

3 generic mfrs Active FDA shortage

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Lidocaine and Epinephrine

Brand: Flavalta · — Part D claims (CY24) · First FDA approval: 1985-09-13

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.